Abstract

Most hepatocellular carcinoma (HCC) patients worldwide do not receive curative treatments. Alternative treatments for most HCC patients include palliative treatments, such as transarterial chemoembolization (TACE), chemotherapy, and radiotherapy. Although statins may be a chemopreventive treatment option for reducing hepatitis B virus (HBV)-and hepatitis C virus (HCV)-related HCC risks, their therapeutic effects are unknown. This study evaluated the effects of statin on HCC patients receiving palliative treatment. Data from the National Health Insurance claims database and cancer registry databases of The Collaboration Center of Health Information Application, Taiwan, were analyzed. We included HCC patients who were treated between January 1, 2001, and December 31, 2010, and followed them from the index date to December 31, 2012. The inclusion criteria were presence of HBV carrier-related HCC, age

Original languageEnglish
Pages (from-to)e1801
JournalMedicine (United States)
Volume94
Issue number42
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Palliative Care
Hepatocellular Carcinoma
Hepatitis B virus
Databases
Information Centers
National Health Programs
Therapeutic Uses
Taiwan
Hepacivirus
Registries
Radiotherapy
Therapeutics
Drug Therapy
Health
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Statin-based palliative therapy for hepatocellular carcinoma. / Shao, Joni Yu Hsuan; Lee, Fei Peng; Chang, Chia Lun; Wu, Szu Yuan.

In: Medicine (United States), Vol. 94, No. 42, 01.10.2015, p. e1801.

Research output: Contribution to journalArticle

@article{ccaee0885eb944e6ad6608bbf7a3cf28,
title = "Statin-based palliative therapy for hepatocellular carcinoma",
abstract = "Most hepatocellular carcinoma (HCC) patients worldwide do not receive curative treatments. Alternative treatments for most HCC patients include palliative treatments, such as transarterial chemoembolization (TACE), chemotherapy, and radiotherapy. Although statins may be a chemopreventive treatment option for reducing hepatitis B virus (HBV)-and hepatitis C virus (HCV)-related HCC risks, their therapeutic effects are unknown. This study evaluated the effects of statin on HCC patients receiving palliative treatment. Data from the National Health Insurance claims database and cancer registry databases of The Collaboration Center of Health Information Application, Taiwan, were analyzed. We included HCC patients who were treated between January 1, 2001, and December 31, 2010, and followed them from the index date to December 31, 2012. The inclusion criteria were presence of HBV carrier-related HCC, age",
author = "Shao, {Joni Yu Hsuan} and Lee, {Fei Peng} and Chang, {Chia Lun} and Wu, {Szu Yuan}",
year = "2015",
month = "10",
day = "1",
doi = "10.1097/MD.0000000000001801",
language = "English",
volume = "94",
pages = "e1801",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "42",

}

TY - JOUR

T1 - Statin-based palliative therapy for hepatocellular carcinoma

AU - Shao, Joni Yu Hsuan

AU - Lee, Fei Peng

AU - Chang, Chia Lun

AU - Wu, Szu Yuan

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Most hepatocellular carcinoma (HCC) patients worldwide do not receive curative treatments. Alternative treatments for most HCC patients include palliative treatments, such as transarterial chemoembolization (TACE), chemotherapy, and radiotherapy. Although statins may be a chemopreventive treatment option for reducing hepatitis B virus (HBV)-and hepatitis C virus (HCV)-related HCC risks, their therapeutic effects are unknown. This study evaluated the effects of statin on HCC patients receiving palliative treatment. Data from the National Health Insurance claims database and cancer registry databases of The Collaboration Center of Health Information Application, Taiwan, were analyzed. We included HCC patients who were treated between January 1, 2001, and December 31, 2010, and followed them from the index date to December 31, 2012. The inclusion criteria were presence of HBV carrier-related HCC, age

AB - Most hepatocellular carcinoma (HCC) patients worldwide do not receive curative treatments. Alternative treatments for most HCC patients include palliative treatments, such as transarterial chemoembolization (TACE), chemotherapy, and radiotherapy. Although statins may be a chemopreventive treatment option for reducing hepatitis B virus (HBV)-and hepatitis C virus (HCV)-related HCC risks, their therapeutic effects are unknown. This study evaluated the effects of statin on HCC patients receiving palliative treatment. Data from the National Health Insurance claims database and cancer registry databases of The Collaboration Center of Health Information Application, Taiwan, were analyzed. We included HCC patients who were treated between January 1, 2001, and December 31, 2010, and followed them from the index date to December 31, 2012. The inclusion criteria were presence of HBV carrier-related HCC, age

UR - http://www.scopus.com/inward/record.url?scp=84948150766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948150766&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000001801

DO - 10.1097/MD.0000000000001801

M3 - Article

C2 - 26496314

AN - SCOPUS:84948150766

VL - 94

SP - e1801

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 42

ER -